公开(公告)号：EP3057965A1

公开(公告)日：2016-08-24

申请号：EP14854037.0

申请日：2014-10-17

Applicant: University Health Network

Inventor： SAMPSON, Peter Brent ,  FEHER, Miklos ,  PAULS, Heinz W.

IPC: C07D413/14 ,  A61K31/5377 ,  A61P35/00

CPC classification number: C07D413/14

Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer. Compound (I)

Abstract translation: 公开了由以下结构式表示的化合物（I）的富马酸盐和马来酸盐，以及它们相应的药物组合物。 1：1富马酸化合物（I）和马来酸化合物（I）的特殊单晶形式的特征在于各种性能和物理测量。 还公开了制备1：1富马酸化合物（I）和1:1化合物（I）马来酸盐的特定结晶形式的方法。 本发明还提供了治疗患有癌症的受试者的方法。 化合物（I）

公开(公告)号：EP2920181A1

公开(公告)日：2015-09-23

申请号：EP13855919.0

申请日：2013-11-15

Applicant: University Health Network (UHN)

Inventor： LIU, Yong ,  PAULS, Heinz W. ,  LAUFER, Radoslaw ,  LI, Sze-Wan ,  SAMPSON, Peter Brent ,  FEHER, Miklos ,  NG, Grace ,  PATEL, Narendra Kumar B. ,  LANG, Yunhui

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract translation: 本教导提供由结构式（1-0）表示的化合物或其药学上可接受的盐。 还描述了药物组合物及其使用方法。

公开(公告)号：EP2417127B1

公开(公告)日：2014-02-26

申请号：EP10761154.3

申请日：2010-04-06

Applicant: University Health Network

Inventor： SAMPSON, Peter Brent ,  Ll, Sze-Wan ,  LIU, Yong ,  PAULS, Heinz W. ,  EDWARDS, Louise G. ,  FORREST, Bryan T. ,  FEHER, Miklos ,  PATEL, Narendra Kumar B. ,  PAN, Guohua

IPC: C07D403/04 ,  A61K31/416 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61P35/00 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14 ,  C07D403/14 ,  C07D471/14 ,  C07D471/04

CPC classification number: A61K31/553 ,  A61K31/416 ,  A61K31/437 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D471/10

公开(公告)号：EP2588110A1

公开(公告)日：2013-05-08

申请号：EP11800027.2

申请日：2011-07-04

Applicant: University Health Network

Inventor： PAN, Guohua ,  MASON, Jacqueline M. ,  WEI, Xin ,  FEHER, Miklos

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P35/00

CPC classification number: A61K31/416 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation, hi particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

公开(公告)号：EP2235004A1

公开(公告)日：2010-10-06

申请号：EP08865534.5

申请日：2008-12-19

Applicant: University Health Network

Inventor： PAULS, Heinz, W. ,  FORREST, Bryan, T. ,  LAUFER, Radoslaw ,  FEHER, Miklos ,  SAMPSON, Peter, Brent ,  PAN, Guohua ,  LIU, Yong ,  LI, Sze-Wan

IPC: C07D403/06 ,  A61K31/416 ,  A61K31/4192 ,  A61P35/00 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

CPC classification number: C07D403/06 ,  C07D401/14 ,  C07D403/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.